Merus N.V.
MRUS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MRUS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2025.
Tracking 4 pipeline candidates · 234 clinical trials · 1 FDA decision for Merus N.V..
Run Merus N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Merus N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
22.6 months
D/E 0.17
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is Merus N.V.'s lead drug candidate?
Merus N.V.'s most advanced tracked candidate is MCLA-129 (Phase 2) for Non-Small Cell Lung Cancer Metastatic.
Who is the CEO of Merus N.V.?
Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of Merus N.V. (MRUS).
Where is Merus N.V. headquartered?
Merus N.V. (MRUS) is headquartered in Utrecht, Netherlands.
What therapeutic areas does Merus N.V. focus on?
Merus N.V. develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Ophthalmology, Cardiovascular, Infectious Disease, Metabolic, Respiratory, Pain, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Reproductive, Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.